". The Company anticipates cash outflows in future quarters will increase in line with the acceleration of the chronic wound drug clinical program, and commercialisation of the aesthetic product."
I get the feeling this July quarterly won't be very good.
The FDA phase 3 process seems to be stalled and they already warned us in the last quarterly (above) that cash will get tighter.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-43
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add TRP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
-0.020(5.56%) |
Mkt cap ! $20.86M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 35.0¢ | 34.0¢ | $43.06K | 123.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4369 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 1100 | 1 |
View Market Depth
| Last trade - 14.00pm 30/09/2024 (20 minute delay) ? |
| TRP (ASX) Chart |